Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romosozumab effects on cognitive function in elderly patients with osteoporosis
ChiCTR2600123752Phase 4Not yet recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of romosozumab in osteoporosis, sponsored by Peking University Third Hospital. Primary endpoint: Change from baseline in MMSE score at 12 months of romosozumab treatment. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
romosozumab
03
Conditions
osteoporosis
Beyond the preview
Go deeper on ChiCTR2600123752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600123752.